Antitumor efficacy of poly(brassylic acid–pentadecandioic acid) copolymer

The drug release profiles of poly(brassylic acid–pentadecandioic acid) P(BA–PA) copolymer containing 5% adriamycin hydrochloride (ADM) in vitro were evaluated. The surface structure of P(BA–PA) copolymer and its drug-loading wafers were studied by atomic force microscopy (AFM). The biocompatibility of P(BA–PA) under mice skin was also evaluated, macroscopic observation and microscopic analysis demonstrated that the copolymer is biocompatible and well tolerated in vivo. Antitumor efficacy of P(BA–PA) copolymers containing 5% adriamycin hydrochloride (ADM) implanted subcutaneously in mice bearing Sarcoma-180 tumor exhibited increased volume doubling time (VDT) (25 ± 1.0 days) compared to plain subcutaneous injection of ADM (7 ± 0.9 days). The studies suggest that P(BA–PA) copolymer as an effective carrier for antineoplastic drug like adriamycin hydrochloride has a very good prospect in the treatment of noumenon tumors.